Wall Street Zen Downgrades Compass Therapeutics (NASDAQ:CMPX) to Sell

Compass Therapeutics (NASDAQ:CMPX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other brokerages have also commented on CMPX. Citizens Jmp started coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 target price on the stock. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “overweight” rating for the company. William Blair started coverage on shares of Compass Therapeutics in a research note on Monday, January 5th. They issued an “outperform” rating for the company. Lifesci Capital began coverage on shares of Compass Therapeutics in a research report on Monday, October 6th. They set an “outperform” rating and a $10.00 target price on the stock. Finally, Leerink Partnrs raised shares of Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $12.23.

Compass Therapeutics Trading Down 1.7%

NASDAQ CMPX opened at $5.70 on Friday. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -12.67 and a beta of 1.45. The business’s 50 day moving average is $5.19 and its two-hundred day moving average is $4.04. Compass Therapeutics has a 12-month low of $1.33 and a 12-month high of $6.25.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06. Equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the period. Creative Planning acquired a new position in shares of Compass Therapeutics during the 2nd quarter valued at about $30,000. Strs Ohio purchased a new position in shares of Compass Therapeutics during the 1st quarter worth about $34,000. Apollon Wealth Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter worth approximately $35,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Compass Therapeutics in the third quarter worth approximately $37,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.